Katharina S Götze1, Claudia Lengerke2. 1. Medizinische Klinik und Poliklinik III, Hämatologie und Internistische Onkologie, Technische Universität München, Ismaninger Str. 22, 81675, München, Deutschland. katharina.goetze@tum.de. 2. Innere Medizin II - Hämatologie, Onkologie, klinische Immunologie und Rheumatologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
Abstract
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is a fairly newly described phenomenon characterized by myeloid cancer-associated somatic mutations detectable in the peripheral blood of individuals without evidence of hematologic disease. Individuals with CHIP have a significantly increased risk of developing a hematologic malignancy, although the overall rate of transformation is low. OBJECTIVE: We review the current state of knowledge on causes of clonal expansion of blood cells as well as identifiable risk factors for progression to overt hematologic malignancy. RESULTS AND CONCLUSION: CHIP is considered a premalignant state and predisposes to the development of hematologic malignancy. Because the overall rate of transformation is low, clear identification and subsequent monitoring of those CHIP individuals at a higher risk is of paramount importance. In the future, prospective studies evaluating preventive and/or preemptive therapeutic strategies may aid in avoiding progression to blood cancer in individuals with CHIP.
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is a fairly newly described phenomenon characterized by myeloid cancer-associated somatic mutations detectable in the peripheral blood of individuals without evidence of hematologic disease. Individuals with CHIP have a significantly increased risk of developing a hematologic malignancy, although the overall rate of transformation is low. OBJECTIVE: We review the current state of knowledge on causes of clonal expansion of blood cells as well as identifiable risk factors for progression to overt hematologic malignancy. RESULTS AND CONCLUSION: CHIP is considered a premalignant state and predisposes to the development of hematologic malignancy. Because the overall rate of transformation is low, clear identification and subsequent monitoring of those CHIP individuals at a higher risk is of paramount importance. In the future, prospective studies evaluating preventive and/or preemptive therapeutic strategies may aid in avoiding progression to blood cancer in individuals with CHIP.
Authors: David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert Journal: Blood Date: 2015-04-30 Impact factor: 22.113
Authors: Florian Zink; Simon N Stacey; Gudmundur L Norddahl; Michael L Frigge; Olafur T Magnusson; Ingileif Jonsdottir; Thorgeir E Thorgeirsson; Asgeir Sigurdsson; Sigurjon A Gudjonsson; Julius Gudmundsson; Jon G Jonasson; Laufey Tryggvadottir; Thorvaldur Jonsson; Agnar Helgason; Arnaldur Gylfason; Patrick Sulem; Thorunn Rafnar; Unnur Thorsteinsdottir; Daniel F Gudbjartsson; Gisli Masson; Augustine Kong; Kari Stefansson Journal: Blood Date: 2017-05-08 Impact factor: 22.113
Authors: Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert Journal: N Engl J Med Date: 2014-11-26 Impact factor: 91.245
Authors: Joseph D Khoury; Eric Solary; Oussama Abla; Yassmine Akkari; Rita Alaggio; Jane F Apperley; Rafael Bejar; Emilio Berti; Lambert Busque; John K C Chan; Weina Chen; Xueyan Chen; Wee-Joo Chng; John K Choi; Isabel Colmenero; Sarah E Coupland; Nicholas C P Cross; Daphne De Jong; M Tarek Elghetany; Emiko Takahashi; Jean-Francois Emile; Judith Ferry; Linda Fogelstrand; Michaela Fontenay; Ulrich Germing; Sumeet Gujral; Torsten Haferlach; Claire Harrison; Jennelle C Hodge; Shimin Hu; Joop H Jansen; Rashmi Kanagal-Shamanna; Hagop M Kantarjian; Christian P Kratz; Xiao-Qiu Li; Megan S Lim; Keith Loeb; Sanam Loghavi; Andrea Marcogliese; Soheil Meshinchi; Phillip Michaels; Kikkeri N Naresh; Yasodha Natkunam; Reza Nejati; German Ott; Eric Padron; Keyur P Patel; Nikhil Patkar; Jennifer Picarsic; Uwe Platzbecker; Irene Roberts; Anna Schuh; William Sewell; Reiner Siebert; Prashant Tembhare; Jeffrey Tyner; Srdan Verstovsek; Wei Wang; Brent Wood; Wenbin Xiao; Cecilia Yeung; Andreas Hochhaus Journal: Leukemia Date: 2022-06-22 Impact factor: 12.883
Authors: Mingchao Xie; Charles Lu; Jiayin Wang; Michael D McLellan; Kimberly J Johnson; Michael C Wendl; Joshua F McMichael; Heather K Schmidt; Venkata Yellapantula; Christopher A Miller; Bradley A Ozenberger; John S Welch; Daniel C Link; Matthew J Walter; Elaine R Mardis; John F Dipersio; Feng Chen; Richard K Wilson; Timothy J Ley; Li Ding Journal: Nat Med Date: 2014-10-19 Impact factor: 53.440
Authors: Judith S Hecker; Luise Hartmann; Jennifer Rivière; Michèle C Buck; Mark van der Garde; Maja Rothenberg-Thurley; Luise Fischer; Susann Winter; Bianka Ksienzyk; Frank Ziemann; Maria Solovey; Martina Rauner; Elena Tsourdi; Katja Sockel; Marie Schneider; Anne S Kubasch; Martin Nolde; Dominikus Hausmann; Alexander C Paulus; Jörg Lützner; Andreas Roth; Florian Bassermann; Karsten Spiekermann; Carsten Marr; Lorenz C Hofbauer; Uwe Platzbecker; Klaus H Metzeler; Katharina S Götze Journal: Blood Date: 2021-11-04 Impact factor: 22.113
Authors: José J Fuster; María A Zuriaga; Virginia Zorita; Susan MacLauchlan; Maya N Polackal; Vanesa Viana-Huete; Alba Ferrer-Pérez; Nuria Matesanz; Andrea Herrero-Cervera; Soichi Sano; Matthew A Cooper; Herminia González-Navarro; Kenneth Walsh Journal: Cell Rep Date: 2020-10-27 Impact factor: 9.423